MAVIRET is a prescription medicine containing a combination tablet of 100mg of glecaprevir and 40mg of pibrentasvir. It is used to treat chronic (long-lasting) hepatitis C virus (HCV) in adults.
This medicine belongs to a group of medicines called direct-acting antiviral agents. Ask your doctor if MAVIRET is right for you.
MAVIRET has risks and benefits. You must not take MAVIRET if you are allergic to any of the medicines contained in MAVIRET, or to any of the inactive ingredients. Do not take it if you have severe liver disease; if you are taking atazanavir or rifampicin containing products. Before you use MAVIRET, tell your doctor if you have or have had liver problems other than hepatitis C infection, HIV infection, hepatitis B infection, or a liver or kidney transplant. Tell your doctor or pharmacist if you are pregnant, trying to become pregnant or if you are breastfeeding or are planning to breastfeed. Do not give MAVIRET to a child under 18. Some medicines and MAVIRET may interfere with each other, so tell your doctor if you are taking medicines containing any of the following: atorvastatin, simvastatin, pravastatin, rosuvastatin, lovastatin, carbamazepine, ciclosporin, darunavir, lopinavir, ritonavir, efavirenz, dabigatran, digoxin, ethinyloestradiol, fluindione, warfarin or other vitamin K antagonists, St John’s wort.
Tell your doctor, nurse or pharmacist if you notice anything that is making you feel unwell. Some of the more common side effects of MAVIRET include feeling very tired, headache and nausea.
If you have any questions about using MAVIRET, including its risks and benefits, how much to use, how and when to use it, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available from your pharmacist, from the Medsafe website www.medsafe.govt.nz or free phone 0800 900 030.
Ask your doctor if MAVIRET is right for you. Normal doctor’s charges apply. Always use strictly as directed. If symptoms continue, or you have side effects, see your health care professional.
© The Hepatitis Foundation of New Zealand 2016